We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+10.72%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.85B
AUM Growth
+$338M
Cap. Flow
+$79.4M
Cap. Flow %
1.36%
Top 10 Hldgs %
45.51%
Holding
707
New
76
Increased
198
Reduced
354
Closed
64

Top Buys

Rank Stock Value
1
TER icon
Teradyne
TER
+$60.1M
2
TSLA icon
Tesla
TSLA
+$32.1M
3
TSEM icon
Tower Semiconductor
TSEM
+$29.6M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$29M
5
PDD icon
Pinduoduo
PDD
+$28.1M

Top Sells

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$77.7M
2
BE icon
Bloom Energy
BE
+$53.1M
3
HOOD icon
Robinhood
HOOD
+$24.9M
4
SAP icon
SAP
SAP
+$24.1M
5
BIDU icon
Baidu
BIDU
+$21.5M

Sector Composition

Rank Sector Weight
1 Technology 51.21%
2 Communication Services 15.38%
3 Consumer Discretionary 13.01%
4 Healthcare 6.62%
5 Consumer Staples 4.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VOR icon
626
Vor Biopharma
VOR
$1.06B
$4.32K ﹤0.01%
+330
New +$6.14K
CABA icon
627
Cabaletta Bio
CABA
$427M
$4.14K ﹤0.01%
+1,891
New +$4.69K
QSI icon
628
Quantum-Si Incorporated
QSI
$153M
$4.09K ﹤0.01%
+3,723
New +$6.06K
TKNO icon
629
Alpha Teknova
TKNO
$266M
$3.99K ﹤0.01%
1,051
-94
-8% -$457
EDIT icon
630
Editas Medicine
EDIT
$399M
$3.92K ﹤0.01%
1,911
-24
-1% -$69
CCCC icon
631
C4 Therapeutics
CCCC
$389M
$3.63K ﹤0.01%
1,903
+440
+30% +$1.04K
SGMT icon
632
Sagimet Biosciences
SGMT
$435M
$3.6K ﹤0.01%
+608
New +$4.37K
ARCT icon
633
Arcturus Therapeutics
ARCT
$165M
$3.54K ﹤0.01%
577
-8
-1% -$86
HUMA icon
634
Humacyte
HUMA
$168M
$3.42K ﹤0.01%
3,565
+158
+5% +$224
CHRS icon
635
Coherus Oncology
CHRS
$217M
$3.27K ﹤0.01%
+2,301
New +$3.35K
CRCL
636
Circle Internet Group
CRCL
$15.3B
$2.93K ﹤0.01%
37
-8
-18% -$827
CRBU icon
637
Caribou Biosciences
CRBU
$146M
$2.92K ﹤0.01%
+1,835
New +$3.85K
CDXS icon
638
Codexis
CDXS
$158M
$2.89K ﹤0.01%
1,775
-167
-9% -$341
UPXI icon
639
Upexi
UPXI
$58.3M
$2.73K ﹤0.01%
1,623
-383
-19% -$1.45K
BDTX icon
640
Black Diamond Therapeutics
BDTX
$95.1M
$2.72K ﹤0.01%
+1,119
New +$3.96K
RANI icon
641
Rani Therapeutics
RANI
$94.8M
$2.51K ﹤0.01%
+1,857
New +$2.8K
PYXS icon
642
Pyxis Oncology
PYXS
$185M
$1.47K ﹤0.01%
1,277
-57
-4% -$201
RIO icon
643
Rio Tinto
RIO
$152B
$240 ﹤0.01%
+3
New +$216
ACHR icon
644
Archer Aviation
ACHR
$3.42B
– –
-13,745
Closed -$132K
ACRV icon
645
Acrivon Therapeutics
ACRV
$61.2M
– –
-650
Closed -$1.18K
AEE icon
646
Ameren
AEE
$30.4B
– –
-118
Closed -$12.3K
AKRO
647
DELISTED
Akero Therapeutics
AKRO
– –
-1,721
Closed -$81.7K
ALEC icon
648
Alector
ALEC
$169M
– –
-2,178
Closed -$6.45K
AMRN
649
Amarin Corp
AMRN
$297M
– –
-434
Closed -$7.11K
ATHM icon
650
Autohome
ATHM
$2.62B
– –
-55,992
Closed -$1.6M
24 25
26
27 28

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.03B AUM 40.55% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return

GF Fund Management's Q4 2025 Portfolio in Review

As of Q4 2025, GF Fund Management held 707 positions worth $5.85B, up 6.1% from $5.51B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

GF Fund Management's Q4 2025 filing shows 76 new, 198 increased, 354 reduced and 64 closed positions. Its largest new stake was Teradyne: 350,137 shares worth $67.8M. The largest sale was Broadcom, an estimated $77.7M.

By sector, the portfolio is most concentrated in Technology at 51% of assets, up from 49% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q4 2025 buy was Teradyne: 350,137 shares worth $67.8M.
  • GF Fund Management added most to Tesla in Q4 2025, an estimated $32.1M increase.
  • GF Fund Management's biggest Q4 2025 reduction was Broadcom, cutting an estimated $77.7M.
  • GF Fund Management fully exited Baidu in Q4 2025, selling an estimated $21.5M.
  • GF Fund Management's ten largest holdings make up 46% of its $5.85B portfolio in Q4 2025.
  • GF Fund Management opened 76 new positions and closed 64 in Q4 2025.
  • GF Fund Management's portfolio value rose 6.1% quarter-over-quarter to $5.85B.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.